CD274 and ovarian cancer: Other immunomodulatory agents, such as antibodies blocking PD-1/PD-L1 pathway (from different sources [154]) are currently tested; for instance, a Phase I study is being conducted to test an anti-PD-L1 moAb as monotherapy in patients with metastatic or advanced solid tumors, including ovarian cancer (NCT01772004).